Tate & Lyle Ventures is a £25M venture capital fund focused on investing in high growth companies in the fields of renewable ingredients, food technologies, biomaterials and industrial processing technologies.
We believe that our insight into financing high growth businesses coupled with Tate & Lyle's expertise in bringing new products to market offers our portfolio companies unique competitive advantages in building successful independent ventures.

23 March 2010
Aquapharm announces the close of a £4.2 million investment from Aescap Venture, Tate & Lyle Ventures, Highlands and Islands Enterprise and NESTA. Alongside the completion of the financing, Aquapharm has appointed the seasoned biotech entrepreneur Simon Best as CEO. A press release of the announcement is available.